Silvan Tuerkcan
Stock Analyst at Citizens
(3.89)
# 665
Out of 5,090 analysts
182
Total ratings
43.82%
Success rate
11.92%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Market Outperform | $25 → $35 | $29.36 | +19.21% | 14 | Nov 26, 2025 | |
| NUVB Nuvation Bio | Maintains: Market Outperform | $8 → $10 | $8.55 | +16.96% | 5 | Nov 20, 2025 | |
| ENGN enGene Holdings | Maintains: Market Outperform | $18 → $21 | $8.07 | +160.22% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $29 → $21 | $9.61 | +118.52% | 14 | Nov 7, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $6 → $8 | $5.05 | +58.42% | 14 | Nov 5, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $20 → $22 | $13.58 | +62.00% | 14 | Nov 4, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $1.71 | +250.88% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $20.29 | +67.57% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $35.87 | +25.45% | 2 | Sep 8, 2025 | |
| EXEL Exelixis | Reiterates: Market Outperform | $50 | $44.36 | +12.71% | 23 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $86 | $56.88 | +51.20% | 16 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $5.77 | +159.97% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $3.74 | +60.43% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $4.36 | +106.42% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $8.18 | +1,366.99% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $2.37 | +617.30% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $5.36 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $1.05 | +280.95% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $7.68 | +173.44% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.37 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $4.74 | +26.58% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $156.94 | +78.41% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $10.22 | +76.13% | 1 | Jan 26, 2023 |
Terns Pharmaceuticals
Nov 26, 2025
Maintains: Market Outperform
Price Target: $25 → $35
Current: $29.36
Upside: +19.21%
Nuvation Bio
Nov 20, 2025
Maintains: Market Outperform
Price Target: $8 → $10
Current: $8.55
Upside: +16.96%
enGene Holdings
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18 → $21
Current: $8.07
Upside: +160.22%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29 → $21
Current: $9.61
Upside: +118.52%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $5.05
Upside: +58.42%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20 → $22
Current: $13.58
Upside: +62.00%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $1.71
Upside: +250.88%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $20.29
Upside: +67.57%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $35.87
Upside: +25.45%
Exelixis
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $44.36
Upside: +12.71%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $56.88
Upside: +51.20%
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $5.77
Upside: +159.97%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $3.74
Upside: +60.43%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $4.36
Upside: +106.42%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $8.18
Upside: +1,366.99%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $2.37
Upside: +617.30%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $5.36
Upside: -
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $1.05
Upside: +280.95%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $7.68
Upside: +173.44%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.37
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $4.74
Upside: +26.58%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $156.94
Upside: +78.41%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $10.22
Upside: +76.13%